Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;3(2):375-81.
doi: 10.2215/CJN.02470607. Epub 2008 Jan 9.

Presentation and outcome of patients with systemic amyloidosis undergoing dialysis

Guillaume Bollée  1 , Bruno Guery, Dominique Joly, Renaud Snanoudj, Benjamin Terrier, Mahmoud Allouache, Lucile Mercadal, Marie-Noëlle Peraldi, Béatrice Viron, Christine Fumeron, Caroline Elie, Fadi Fakhouri
Affiliations

Presentation and outcome of patients with systemic amyloidosis undergoing dialysis

Guillaume Bollée et al. Clin J Am Soc Nephrol. 2008 Mar.

Abstract

Background and objectives: Light chain (AL) and secondary (AA) amyloidosis usually present as a systemic disease frequently involving the kidney and leading to ESRD. Data regarding patients with AA or AL amyloidosis undergoing dialysis remain scarce.

Design, setting, participants, & measurements: We retrospectively studied patients with AA or AL amyloidosis who started dialysis in five French centers between January 1, 1995 and December 31, 2005.

Results: We identified 19 patients with AL and 20 patients with AA amyloidosis undergoing dialysis. Patients with AL amyloidosis had shorter time from diagnosis to dialysis (25.2 versus 69.3 mo, P < 0.05) and more extrarenal amyloidosis, especially cardiac (63.2 versus 5%, P < 0.0001). Mean duration of follow-up was 37.4 and 31.8 mo for patients with AL and AA amyloidosis, respectively. Fifteen patients (78.9%) with AL and three patients (15%) with AA amyloidosis died on dialysis. Median survival was shorter in patients with AL (26 mo) than AA amyloidosis [not definable (ND)] (P < 0.02). Sepsis and cardiac deaths were the main causes of mortality. Prognosis factors for death at 1 yr were AL type (P < 0.01), cardiac amyloidosis [odds ratio (OR) = 18, P < 0.01], heart failure (OR = 8, P < 0.04), and shorter time from diagnosis to dialysis (6.1 versus 56 mo, P < 0.03). Multivariate analysis indicated that AL type (P = 0.02), but not cardiac amyloidosis was independently associated with global mortality.

Conclusions: Survival of patients with amyloidosis undergoing dialysis, especially AL type, is probably better than previously reported. However, mortality is higher in AL than AA type, especially in the setting of cardiac involvement.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier curves of survival during dialysis in patients with AA or AL amyloidosis (A) and in patients with (cardiac +) or without (cardiac −) cardiac amyloidosis (B). Ticks indicate censored subjects (lost to follow-up or still alive on dialysis).
See this image and copyright information in PMC

References

    1. Dember L: Amyloidosis associated Kidney Disease. J Am Soc Nephrol 17: 3458–3471, 2006 - PubMed
    1. Gertz MA, Kyle RA, O'Fallon WM: Dialysis support of patients with primary systemic amyloidosis: A study of 211 patients. Arch Intern Med 11: 2245–2250, 1992 - PubMed
    1. Moroni G, Banfi G, Montoli A, Bucci A, Bertani T, Ravelli M, Pozzi C, Leonelli M, Lupo A, Volpi A, et al Clin Nephrol 2: 81–85, 1992 - PubMed
    1. Martinez-Vea A, Garcia C, Carreras M, Revert L, Oliver JA: End-stage renal disease in systemic amyloidosis: Clinical course and outcome on dialysis. Am J Nephrol 4: 283–289, 1990 - PubMed
    1. Sanai T, Nanishi F, Nagata M, Hirano T, Suematsu E, Esaki Y, Miyahara H, Iida M: Role of amyloidosis in determining the prognosis of dialyzed patients with rheumatoid arthritis. Rheumatol Int 4: 363–367, 2007 - PubMed